Pemphigus vulgaris (PV) is a rare immune-mediated skin disorder, typically occurring in middle-aged and older adults, that involves painful blistering of the skin and mucous membranes. While many patients are well controlled on systemic corticosteroid treatment, steroid-sparing therapy can be desirable for treating moderate to severe forms of the disease, and rituximab is one such agent to show promise in this indication.
Pemphigus vulgaris (PV) is a rare immune-mediated skin disorder, typically occurring in middle-aged and older adults, that involves painful blistering of the skin and mucous membranes. The disease has a relapsing and remitting course that can, in severe instances, be life-threatening. While many patients are well controlled on systemic corticosteroid treatment, steroid-sparing therapy can be desirable for treating moderate to severe forms of the disease, and rituximab is one such agent to show promise in this indication.
A recent, single-center, retrospective, case-control study reported on 40 patients with PV, treated at Duke University from 1999 to 2015, who required steroids plus conventional adjuvant therapy with agents such as mycophenolate mofetil, azathioprine, adalimumab, or infliximab (n = 27), or steroids and conventional therapy followed by rituximab (n = 13).
The group who received rituximab was able to reduce median monthly prednisone intake from pre-rituximab levels of 658.6 mg per month (interquartile range [IQR], 600.0-724.8) to 177.2 mg per month (IQR, 97.3-309.5) after starting rituximab.
There was no difference in monthly prednisone intake between the conventional therapy group and the rituximab group after treatment, but the patients who received conventional treatment only had significantly lower monthly prednisone intake (141 mg per month; IQR, 79.3-428.8) versus the pre-rituximab patients. There was no difference in the likelihood of being able to discontinue prednisone between the patient groups.
Additionally, patients who received rituximab had lower numbers of infections, hospital admissions, and emergency department visits per year after initiating rituximab.
Between the patients receiving conventional treatment alone and those receiving rituximab, there was no difference in the likelihood of complete remission, but those who received rituximab gained remission in a median time period of 6 months, while those who received conventional treatments gained remission after a median of 10.7 months.
“Rituximab may facilitate remission by a different, more efficient mechanism compared to [conventional therapy] as it decreased prednisone intake dramatically and significantly in the [rituximab] group despite their more severe disease,” write the authors, who add that even those who respond well to conventional drugs may benefit from earlier intervention with rituximab in terms of fewer infections, hospitalizations, laboratory draws, and clinic visits.
Reference
AgarwalA, Hall RP, Bañez LL, Cardones AR. Comparison of rituximab and conventional adjuvant therapy for pemphigus vulgaris: a retrospective analysis [published online September 25, 2018]. PLOS One. https://doi.org/10.1371/journal.pone.0198074.
Study Documents HCPs’ Experiences of a Mandatory Switch to Inform Future Transitions
December 2nd 2023A survey explores the experiences of health care providers (HCP) in New Zealand throughout the transition process following a mandatory switch from the adalimumab originator (Humira) to a biosimilar in 2022.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Study: Biosimilar Use, Dose Rounding Produce More Cost Savings Than Either Strategy Alone
November 18th 2023A retrospective study of New England patients receiving trastuzumab or bevacizumab found that combining dose rounding and biosimilar use resulted in greater cost savings than either strategy alone.